Form 4: NewAmsterdam Pharma Co N.V. Executive Juliette Berangere Audet Reports Transaction
SEC Form 4 Filing
Juliette Berangere Audet, Chief Business Officer of NewAmsterdam Pharma Co N.V., reports a transaction involving ordinary shares.
Summary
- On September 26, 2024, Juliette Berangere Audet, the Chief Business Officer of NewAmsterdam Pharma Co N.V. (NAMS), reported a transaction.
- The transaction involved ordinary shares.
- Audet acquired 1,104 ordinary shares at a price of $15.7.
- Following the reported transaction, Audet beneficially owns 1,104 ordinary shares.
Sentiment
Score: 5
Explanation: This is a routine filing; the sentiment is neutral as it simply reports a transaction.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, which is important for maintaining investor confidence.
Stakeholder Impact
- The transaction provides transparency to shareholders regarding insider activity.
Key Dates
| Date | Description |
|---|---|
| 09/26/2024 | Date of the transaction involving ordinary shares. |
| 09/30/2024 | Date of signature for the report. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.